Mercaptopurine (Purixan)
Defines medical necessity, prior authorization, and coverage criteria for Purixan (mercaptopurine oral suspension) for treatment of acute lymphoblastic leukemia and related oncology uses across Centene lines of business.
Added redirection to generic oral suspension and revised redirection verbiage related to mercaptopurine tablets.
Added step therapy bypass for Illinois HIM requests per IL HB 5395.
Clarified that member must use generic mercaptopurine oral suspension unless contraindicated or adverse effects occur, and that oncology step therapy prohibitions in certain states allow bypass.
Modified commercial approval duration from length of benefit to 12 months or duration of request, whichever is less.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.